We have reported previously the design of a RIAD (RIanchoring disruptor) peptide that specifically displaces PKA (protein kinase A) type I from the AKAP (A-kinase-anchoring protein) ezrin, which is present in the immunological synapse of T-cells. This increases immune reactivity by reducing the threshold for activation and may prove a feasible approach for improving immune function in patients with cAMP-mediated T-cell dysfunction. However, the use of RIAD in biological systems is restricted by its susceptibility to enzymatic cleavage and, consequently, its short half-life in presence of the ubiquitous serum peptidases. In the present study, carefully selected nonnatural amino acids were employed in the design of RIAD analogues with improved stability. The resulting peptidomimetics demonstrated up to 50-fold increased half-lives in serum compared with RIAD, while maintaining similar or improved specificity and potency with respect to disruption of PKA type I-AKAP interactions.
INTRODUCTION
PKA (protein kinase A or cAMP-dependent protein kinase) has a broad array of substrates and relies on subcellular localization to maintain fidelity of its actions [1] . The PKA holoenzyme consists of two catalytic subunits bound to a regulatory subunit dimer and encompasses two main classes of isoenzymes, called PKA type I and type II, as determined by the regulatory subunit isoform (RI or RII) [2] . While inactive, the regulatory subunit dimer maintains the catalytic subunits in a dormant state. Upon the sequential binding of four molecules of cAMP, however, conformational changes in the regulatory subunit dimer release the catalytic subunits, which, in turn, phosphorylate nearby substrate proteins [2] . Thus it is the local availability of cAMP that determines the activation status of PKA. Importantly, targeting of the different PKA isoenzymes to distinct subcellular domains enables them to be activated separately by distinct pools of cAMP [3] , which are generated in response to ligation of membraneassociated GPCRs (G-protein-coupled receptors) that activate nearby ACs (adenylate cyclases). The cAMP pools, in turn, are spatially and temporally restricted by the activity of specific cAMP PDEs (phosphodiesterases) sequestered in the vicinity that rapidly hydrolyse cAMP into 5 -AMP. Hence the specificity of PKA signalling is partly ensured by the localized expression of cAMP in distinct, short-lived, subcellular pools [4] .
The targeting of PKA to discrete domains of the cell is achieved through specific docking to a series of scaffolding proteins known as AKAPs (A-kinase-anchoring proteins) [5] . These anchoring proteins tether PKA through a helical motif known as the AKB (A-kinase-binding) domain, which binds the D/D (dimerization/docking) domain of the PKA regulatory subunit dimer [6] . Crystallographic studies have revealed that the D/D domain forms a hydrophobic groove in the interface of the two monomers that accepts the amphipathic AKB helix of the AKAP [7, 8] , and that PKA-AKAP specificity is a result of variations in this groove between different PKA isoforms [9, 10] . Although it was previously believed that only PKA type II was anchored by AKAPs, more recent evidence demonstrates anchoring of PKA type I as well [11] [12] [13] , and some studies have even indicated the existence of type I-specific AKAPs [14, 15] . Thus isoform-specific anchoring appears to play a significant role in maintaining the specificity of PKA signalling.
Anchoring disruptors that can prevent the anchoring of PKA to AKAPs have been used extensively to delineate the functions of PKA in different cells and tissues [3, [16] [17] [18] [19] . The first anchoring disruptor to be developed was the Ht31 peptide, constructed after the AKB helix of AKAP-Lbc [20, 21] . Its ability to disrupt the anchoring of PKA was first demonstrated in studies of the AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid)-type glutamate receptor in cultured hippocampal neurons and the L-type Ca 2+ channel of skeletal muscle cells [22, 23] . More recently, isoform-specific anchoring disruptors based on in silico modelling have been developed, including the RIAD (RI-anchoring disruptor) [17] and AKAP-IS (AKAP-in silico) [24] peptides. In contrast with the Ht31 peptide, which is dual-specific, these selectively bind RI or RII respectively, facilitating the targeted disruption of either type I or type II PKA. Furthermore, an improved RII-anchoring disruptor known as SuperAKAP-IS has been designed through site-specific substitutions of the AKAP-IS sequence, yielding a disruptor even more specific for RII [7] . The RIAD and SuperAKAP-IS peptides constitute powerful tools for elucidating the roles of type I and type II PKA in specific signalling pathways and for unravelling their complex interplay with other signalling networks. However, Abbreviations used: Aad, α-aminoadipic acid; Abu, α-aminobutyric acid; AC, adenylate cyclase; AKAP, A-kinase-anchoring protein; AKAP-IS, AKAPin silico; AKB, A-kinase-binding; 8-CPT-cAMP, 8-(4-chlorophenylthio)-cAMP; Csk, C-terminal Src kinase; D/D, dimerization/docking; Fmoc, fluoren-9-ylmethoxycarbonyl; GST, glutathione transferase; IL-2, interleukin-2; MALDI, matrix-assisted laser-desorption ionization; NmL, N-methyl-leucine; Orn, ornithine; PDE, phosphodiesterase; PDSM, position-dependent scoring matrix; PKA, protein kinase A; RIAD, RI-anchoring disruptor; TBS, Tris-buffered saline; TBS-T, TBS with 0.01 % Tween; TCR, T-cell receptor; TFA, trifluoroacetic acid; TOF/TOF, time-of-flight/time-of-flight. 1 To whom correspondence should be addressed (email kjetil.tasken@biotek.uio.no). 
the use of anchoring disruptor peptides in vivo has so far been precluded by their susceptibility to enzymatic degradation. Efficient delivery of anchoring disruptor peptides across the cell membrane is a prerequisite for achieving physiological effects and requires the incorporation of a targeting vector in the peptide sequence. The first cell-permeant anchoring disruptor peptide (S-Ht31) contained a lipid carrier in the form of stearic acid that was thought to initiate translocation of the peptide by facilitating its insertion into the plasma membrane [25] . However, the most frequently used cell-permeant peptide vectors include the HIV-1 Tat-(48-60) peptide and polyarginine tails of various lengths (up to R 16 ; single-letter amino-acid notation is used throughout), both of which are positively charged and rich in arginine residues [26] . Recently, a cell-permeant analogue of AKAP-IS was generated by conjugation to a Tat-derived decapeptide for assessment of the compartmentalized effects of PKA on insulin secretion in pancreatic β-cells [27] . Correspondingly, RIAD was rendered cell-permeant by the introduction of a polyarginine tail and was shown to restore TCR (T-cell receptor) signalling inhibited by cAMP in human peripheral blood T-cells [17] . The translocation of Tat-or polyarginine-conjugated peptides across the cell membrane depends to a certain extent on uptake by macropinocytosis, but non-endocytic mechanisms might contribute to the translocation as well [26] .
In resting T-cells, low-level cAMP production permits continual activation of PKA type I, which prevents activation of the T-cell by phosphorylating and activating the Src-family kinase Csk (C-terminal Src kinase) [28, 29] . Activated Csk phosphorylates the inhibitory site (Y 505 ) of Lck, resulting in early truncation of TCR signalling when the TCR is activated in the absence of co-stimuli [30] . This potentially constitutes an important inhibitory mechanism, protecting the organism from unsolicited immune activation and autoimmunity. In the face of infection or other serious threats, the refractory state of the resting T-cell is overcome by the expression of co-stimulatory molecules on APCs (antigen-presenting cells), which upon ligation to the T-cellexpressed co-receptor CD28 foster recruitment of PDEs such as PDE4 to the immunological synapse [31, 32] . The recruited PDEs reduce the amount of cAMP available for the activation of PKA and, consequently, release the T-cell from PKA-mediated inhibition. As sustained activation of the T-cell generates a surge in cAMP levels through the induction of ACs, PKA may also act in a feedback fashion to terminate TCR signalling [33] .
We know that PKA type I is the isoenzyme that is most abundant in the lipid rafts of T-cells, and we have functional findings supporting the role of PKA type I in the cAMP/PKA/Csk inhibitory pathway [28, 35, 36] . However, we lack the tools to investigate the implications of this pathway in vivo. Moreover, dysfunctional PKA signalling has been linked to the development of AIDS [37] , advocating further the development of specific inhibitors of PKA type I that are suitable for in vivo studies. Furthermore, although some redundancy has been reported, the abundance of PKA isoforms and AKAPs indicates a high degree of specificity in PKA signalling. Consequently, the use of isoformspecific disruptors of PKA signalling may offer an interesting vantage point for exploring the signalling networks converging on PKA. In this respect, the RIAD peptide specifically abrogates the localization of PKA type I by disrupting its binding to AKAPs [17] . However, the use of this peptide has been hampered by its limited stability in serum. In the present study, we demonstrate how this limitation was overcome by the careful introduction of non-natural amino acids to yield peptidomimetics of improved enzymatic stability. We present several enhanced analogues of RIAD that may be used in prolonged studies in vitro, as well as in animal studies.
EXPERIMENTAL

Peptide synthesis
The peptides were synthesized on an Intavis MultiPep robot (Intavis Bioanalytical Instruments) using Fmoc (fluoren-9-ylmethoxycarbonyl) protection chemistry and were purified to >95 % purity by HPLC. The purified peptides were verified by MS (see Table 1 for the peptide sequences).
HPLC
Peptide analysis and purification were performed on a Varian HPLC system using 0.1 % TFA (trifluoroacetic acid) in water (mobile phase A) and 0.075 % TFA in acetonitrile (mobile phase B) and C 18 microsorb analytical and preparative columns (Varian). For purification, peptide-specific protocols were employed that spanned 8 % gradients over 14 min. In the analytical setup for stability studies, a fixed 14-min gradient from 20 to 60 % of mobile phase B was used for all of the peptides.
MALDI-TOF/TOF-MS (matrix-assisted laser-desorption ionization-time-of-flight/time-of-flight MS)
An ULTRAFLEX II (Bruker Daltonics) MALDI-TOF/TOF mass spectrometer was used after external calibration. The samples were analysed in the MS mode (for generation of peptide mass fingerprints) as well as in the TOF/TOF mode. The matrix used was 20 mg/ml α-cyano-4-hydroxycinnamic acid in 0.3 % aqueous TFA/acetonitrile (2:1, v/v). The samples were applied on to a stainless steel sample holder and introduced into the mass spectrometer after drying. MS spectra were transformed into peak lists using the software flexAnalysis v2.4 (Bruker Daltonics).
Peptidase cleavage prediction and peptide modelling
A peptidase cleavage prediction analysis was performed using the Protean v8.0 software (DNAStar). The results of this analysis were compiled with information from a recent review [38] to arrive at a consensus for the preferred cleavage sites of some of the most abundant human serum peptidases.
The RIAD peptide and its analogues were modelled using PyMOL TM v0.99 (DeLano Scientific).
Autospot peptide array
Peptide spots were synthesized with Fmoc protection chemistry on cellulose membranes using a Multipep automated peptide synthesizer (Intavis Bioanalytical Instruments) as described previously [39] .
AlphaScreen assay
The RIAD analogues were tested with respect to interactions with the R subunits of PKA type I and type II respectively, using an AlphaScreen (Amplified Luminescence Proximity Homogenous assay) set-up with biotinylated RIα or RIIα conjugated to streptavidin-coated donor beads and GST (glutathione transferase)-tagged D-AKAP1 coupled to anti-GST-coated acceptor beads. The assay was performed as described previously [40] . Briefly, 20 nM or 1 nM GST-D-AKAP1 was incubated with 20 nM biotinylated RIα or 1 nM biotinylated RIIα respectively, in the presence of different concentrations of peptide for 15 min on ice in a total of 15 μl of assay buffer [0.1% BSA, 100 mM NaCl and 25 mM Hepes (pH 7.4)]. Following the addition of 5 μl of acceptor beads, the reaction mixture was incubated on ice for 30 min. Subsequently, 5 μl of donor beads was added and the reaction was incubated at room temperature (22 • C) for another 90 min (RIα) or 60 min (RIIα) before being read on an EnVision TM multiplate reader (PerkinElmer). Acceptor and donor beads were added at a final concentration of 20 μg/ml. IC 50 values were calculated from non-linear regression analyses performed in SigmaPlot v8.0 (SPSS).
Isolation of primary T-cells
Circulating primary T-cells were isolated from buffy coats of healthy donors using the RosetteSep TM Human T-cell Enrichment cocktail (StemCell Technologies), according to the manufacturer's instructions. Briefly, the buffy coat was incubated for 20 min with the enrichment cocktail, followed by a 1:1 dilution with PBS and separation of the unrosetted mononuclear cells (predominantly T-lymphocytes) by IsopaqueFicoll (Lymphoprep TM ; Nycomed) density gradient centrifugation (800 g for 25 min at 4
• C). The isolated T-cells were cultured in RPMI 1640 GlutaMAX (Gibco) containing 10 % (v/v) fetal bovine serum (Gibco), penicillin (100 units/ml)/streptomycin (0.1 mg/ml), 1 mM sodium pyruvate and 1× non-essential amino acids (the latter three from PAA). T-cell lysates were prepared by incubating isolated T-cells in freshly made aqueous lysis buffer containing 100 mM NaCl, 10 mM sodium pyrophosphate, 1 % (v/v) Triton X-100, 50 mM sodium fluoride, 1 mM PMSF, 1 mM Na 3 VO 4 , 5 mM EDTA and 50 mM Hepes (pH 7.4) for at least 30 min on ice, followed by centrifugation at 14 000 g to remove DNA and debris.
Overlays
Overlays were performed using radiolabelled recombinant bovine RIα or murine RIIα, as described previously [41] . Briefly, cellulose membranes with immobilized peptide were blocked in Blotto {5 % (w/v) non-fat dry milk, 0.1 % BSA and 0.05 % Tween 20 in TBS [Tris-buffered saline; 50 mM Tris/HCl (pH 7.4) and 1.5 M NaCl]}. Purified recombinant R (4 μg) was radiolabelled with [γ -
32 P]ATP (1.4 μCi/μl) in the presence of the purified catalytic subunit of PKA (C) in a reaction buffer consisting of 50 mM Mops (pH 6.8), 50 mM NaCl, 2 mM MgCl 2 and 1 mM DTT (dithiothreitol). Labelled R was separated from free [γ -32 P]ATP by gel filtration (G-50 Sepharose). Specific activity was assessed by liquid-scintillation counting (1600TR Tri-Carb; Packard Instruments). Overlays were performed overnight at room temperature using 1 × 10 6 c.p.m./ml of radiolabelled R in TBS-T (TBS with 0.01 % Tween 20). The membranes were washed five times in TBS-T before autoradiography.
Solid-phase pull-down
Lysate from 4 × 10 7 peripheral blood T-lymphocytes was incubated overnight at 4
• C with peptide synthesized in triplicate on a cellulose membrane. The membranes were subsequently washed twice (20 min) in high-salt lysis buffer [20 mM Hepes (pH 7.4), 5 mM EDTA and 1 M NaCl]. Bound R was eluted by boiling in SDS/PAGE sample buffer, and the eluates were analysed by Western blotting using mouse anti-RIα and anti-RIIα antibodies (BD Transduction Laboratories).
Peptide loading and in vitro stimulation of T-cells
Purified T-cells were loaded for 2 h at 37
• C with 25 μM of the respective RIAD analogue synthesized with nine arginine residues C-terminally to facilitate uptake over the cell membrane. A total of 2 × 10 5 cells were subsequently incubated for 15 min without or with 8-CPT-cAMP [8-(4-chlorophenylthio)-cAMP] at different concentrations, followed by stimulation with anti-CD3/ CD28-coated beads (1.6 beads/cell; Dynabeads ® CD3/CD28 Tcell Expander; Invitrogen) for 16 h. Supernatants were harvested and IL-2 (interleukin-2) levels were determined by ELISA, according to the manufacturer's instructions (R&D Systems).
Statistical analysis
Non-linear regression analyses for the calculation of IC 50 values upon AlphaScreen and the determination of plasma half-lives were performed using SigmaPlot v8.0 (SPSS). The comparison of peptides with respect to IL-2 production was performed using the Mann-Whitney U test in SPSS v16.0. P values are two-sided and considered significant at P < 0.05.
RESULTS
RIAD
The design of RIAD was initially based on alignment analyses of known RIα-binding-anchoring proteins. Specifically, the linear R-binding domains of D-AKAP1, ezrin and AKAP82 were aligned and analysed using the MEME algorithm published by Bailey and Elkan [42] . This led to the identification of a PDSM (position-dependent scoring matrix) consensus sequence of 20 amino acids that was subsequently optimized through sitespecific substitutions guided by peptide array overlays with radiolabelled RIα and RIIα respectively. The final peptide, optimized for RIα binding, constituted a truncated 18-mer differing from the original PDSM peptide by three substitutions. This peptide, with the sequence LEQYANQLADQIIKEATE, had an apparent 50-fold selectivity for RIα over RIIα and disrupted the functions of PKA type I, for which reason it was named RI-Anchoring Disruptor (RIAD). It was the first RI-specific anchoring disruptor and was intended to delineate the physiological roles of PKA type I. However, its susceptibility to degradation by serum peptidases has hampered its utilization in prolonged in vitro studies and may preclude its use in vivo. Hence the present study addressed the stability of the RIAD peptide and sought to design RI-specific anchoring disruptors of improved enzymatic stability.
Short half-life of RIAD in serum may limit its effectiveness in vivo
The half-life of RIAD in human serum was determined by incubation at 37
• C in serum of different concentrations, serially diluted with PBS. Samples were withdrawn at several different time points and serum proteins were precipitated by the addition of TFA. The cleared samples were subjected to HPLC, and the resulting chromatogram was used to estimate the amount of remaining RIAD and to follow the emergence of metabolites. The amount of intact peptide was assessed by reading the height of the corresponding peak in the HPLC trace. Degradation of RIAD was evident by reduced peak height after 1 h of incubation with the highest serum concentration used in the study (30 %). The peak heights at each time point were plotted on a linear time scale and the half-life was determined by single two-parameter exponential regression ( Figure 1A) . Subsequently, the half-lives at different serum concentrations were plotted on a logarithmic scale, and the half-life of RIAD in 100 % serum was estimated by non-linear (two-parameter power) regression and extrapolation of the resulting curve ( Figure 1B) . Our results suggest that the halflife of RIAD in human serum is approx. 1.5 h, implicating a 94 % elimination of the peptide within 6 h.
Concerned with the short serum half-life of the RIAD peptide, we wished to extend its stability by site-specific modifications, hoping to make RIAD peptidomimetics that were more suitable for use in vivo. Initially, we performed a prediction of the protease fragmentation of RIAD using the Protean ® software from DNAStar. The results of this prediction were corroborated with information from the literature, and eventually the six most prominent serum proteases were short-listed for the prediction outlined in Figure 1(C) . However, the actual predictive value of such an exercise is limited by our incomplete knowledge of the proteases that would target RIAD in different compartments in vivo. Taking a more focused approach, therefore, we decided to analyse more closely the metabolites that resulted from enzymatic degradation of RIAD in serum, which is the compartment first encountered by peptides administered intravenously. The metabolites resulting from incubation of RIAD in 30 % (v/v) serum for different periods of time were sequenced by MS (TOF/TOF) following MALDI. From this analysis, it became clear that the degradation of RIAD progressed in a well-ordered manner, in which the N-terminal amino acids were removed sequentially by exopeptidase activity. As shown in Figure 1(D) , the most abundant metabolites at 6 as well as 24 h of incubation were the N-terminally mono-and di-truncated RIAD metabolites (peptides B and C respectively). The minor ruffles in the baseline at smaller m/z values may indicate the presence of small amounts of other metabolites as well, but these were too scarce to be sequenced. The abundance of the mono-and di-truncated metabolites suggests that these constitute the rate-limiting steps of RIAD degradation and that the majority of RIAD molecules are processed through these steps. Hence it appears that an effort to improve the stability of RIAD should primarily target the N-terminal amino acids of the peptide. 
Modification of RIAD requires attention to the overall structure of the peptide
The binding of RIAD to the RI D/D domain serves to prevent subcellular targeting of PKA type I and thereby disrupt its function. Previous studies have indicated a helical structure of the RIAD peptide [17] . Upon binding, RIAD is thought to extend its hydrophobic side chains towards hydrophobic residues of RIα in the base of the D/D groove, while exposing its hydrophilic side chains to solvent. However, the structure of an RIα dimer bound to an AKAP (or a peptide derived from the AKB domain) has not yet been resolved, precluding detailed molecular modelling. In general, however, it is well established that the AKB domain of AKAPs carries an α-helical structure, either constitutively or as an induced conformation upon binding to the D/D domain of the R subunit [6, 43] .
The D/D domains of RIα and RIIα differ in several respects. First, the D/D domain of RIIα appears capable of accommodating a greater variety of AKAPs than does RIα [13, 14, 43] . This relates to conformational differences between the two isoforms, in which the RIα isoform has a more conformationally restricted surface and presents with a deep cleft in the unbound state, whereas the RIIα isoform has a more extended conformation and a less restricted surface [6] . Secondly, the RIα homodimer
Figure 2 Identification of substitution-tolerant residues in RIAD
Autoradiography of two-dimensional peptide arrays with RIAD and its single-substituted analogues. Every residue in the native RIAD peptide (given above the arrays) was replaced one-by-one with each of the 20 natural amino acids (given to the left of the arrays), and the resulting peptides were synthesized in a two-dimensional matrix on cellulose membranes. The membranes were incubated with 32 P-labelled recombinant RIα (A) or RIIα (B), and the ability of the peptides to bind either of these two PKA regulatory subunits was determined by autoradiography. The first two rows and the white circles in the array correspond to the native RIAD sequence. Black arrows indicate the positions in the RIAD sequence that may be substituted without losing RIα affinity, whereas yellow columns are indicative of residues that do not tolerate substitutions. Substitutions with proline residues are generally not tolerated, and are indicated by black boxes in the arrays.
generally binds the AKAP with a lower affinity than does RIIα [44] . Binding of an AKAP to the RIIα homodimer is supported by strong hydrophobic interactions that are reinforced by the exclusion of water from the interacting regions. On the other hand, the surface of RIα contains hydrophilic side chains that may contribute to the AKAP binding and downplay the role of hydrophobic interactions. However, the propensity of RIα to bind AKAPs with a lower affinity does not preclude the synthesis of AKAP peptides that bind with a higher affinity and that can be used to displace PKA type I from AKAPs in vitro or in vivo [6] .
A two-dimensional peptide array substitution study, in which each of the natural amino acids (given on the left-hand side of the arrays in Figure 2 ) was substituted sequentially for each amino acid in the RIAD sequence (given above the array in Figure 2 ), was performed in order to determine the positions in the sequence that were eligible for modification. The different monosubstituted peptides were synthesized on a cellulose membrane and subjected to overlay with 32 P-labelled recombinant RIα and RIIα respectively ( Figure 2 ). As shown previously [17] , RIAD has little or no binding to RII, yet binds strongly to RI. The overlay revealed a specific pattern of amino acids in the RIAD sequence that could not easily be substituted without causing the loss of PKA affinity (resulting in dimmer spots) and/or specificity (increased binding to RII, as observed by denser spots on the RII overlay) and, correspondingly, a set of positions in the peptide that were tolerant to substitutions (the intensity of the spots was maintained). This distinct pattern of intermittent tolerant and substitution-sensitive positions compares well with a helical structure, where the residues that are crucially involved in RIα binding are, conceivably, less tolerant than the residues exposed only to solvent. 4 residue, on the other hand, appears to be involved in a specific interaction with another aromatic structure, since this position does accept substitution with the aromatic amino acid phenylalanine. The majority of non-tolerant residues are thought to cluster to one face of the peptide, creating an amphipathic structure with the hydrophilic amino acids largely facing the opposite way and not contributing directly to binding [17] . Thus the tolerability of the hydrophilic residues for substitutions may be explained by their limited involvement in RI binding (illustrated in Figure 3C ). The importance of the helical structure of the peptide is corroborated further by the fact that introducing a proline residue in either position abrogated binding to both RIα and RIIα. Hence any modification of the RIAD peptide must be made in accordance with the fact that several of its residues do not tolerate even minor changes.
Stabilizing RIAD while retaining PKA-binding properties D-Amino acids have been shown to enhance the resilience of peptides to enzymatic degradation [45, 46] . We tested whether D-amino acid substitutions could be used to improve the stability of RIAD by assessing the effect of these substitutions on PKA binding properties. Mono-substituted RIAD analogues were spot-synthesized on solid phase and subjected to overlay with radiolabelled RIα and RIIα respectively. The R overlay revealed that the introduction of a D-amino acid anywhere in the RIAD sequence resulted in a loss of function, as the analogue no longer bound RIα ( Figure 3A) . The analogues in which a partial affinity for RIα was retained had typically been substituted in one of the tolerant hydrophilic amino acid positions (i.e. and E 18 ; Figure 3A) . The E 18 e analogue was, perhaps, the only interesting mono-D-substituted analogue, as it still carried some affinity for RIα and discriminated well against RIIα. If this was to be a potent analogue, stability might have been ensured by the interruption of C-terminal exopeptidase activity; however, further studies showed only limited effects of this substitution on the overall stability of the RIAD peptide, which is in line with our MS analyses indicating predominantly N-terminal degradation of the peptide.
Clearly, the introduction of a D-amino acid into the RIAD sequence had detrimental effects on RIα binding. This could be explained by the inverted stereochemistry of D-amino acids, conceivably creating a kink in the peptide helix and causing a distortion almost comparable with the one resulting from the introduction of a proline residue. It appears likely, therefore, that a modification which drastically alters the helical structure of RIAD will abrogate RIα binding.
Another approach that may appear more subtle is the introduction of unnatural L-amino acids. Four different unnatural amino acids were used (for structures, see Table 2 ): NmL (Nmethyl-leucine; for N-terminal capping), Abu (α-aminobutyric acid; non-polar), Aad (α-aminoadipic acid; acidic) and Orn (ornithine; basic). These were substituted for the amino acids of RIAD as shown in Table 2 . Results from RIα and RIIα overlays indicated that the binding properties were retained with minor changes in several of the substituted peptides ( Figure 3B) . The amino acids shown in Figure 2 to be substitution-tolerant were also the ones that most easily accepted an unnatural amino acid in its place, sustaining the supposition that RIAD assumes or maintains an amphipathic α-helical structure upon binding to the RIα dimer. The hydrophobic residues of RIAD appear to be critical for this interaction and may therefore be expected to face the binding interface, whereas the hydrophilic residues remain exposed to solvent (illustrated in Figure 3C ). RIAD analogues were designed through modification of the identified substitutiontolerant residues. In Figure 3(D) , RIAD is shown along with some of the analogues to highlight (in green) the residues that have been modified and to indicate the level of modification that has been introduced in each analogue (for sequences, see Table 1 ). With the exception of the substitution of NmL for the N-terminal leucine residue (L 1 ), the residues that were least tolerant to substitutions (shown in red in Figure 3C ), and thus thought to interact with the D/D domain, were left untouched.
Improving the stability of RIAD with site-specific side-chain modifications A series of peptidomimetics containing unnatural amino acids at multiple positions were screened for PKA-binding properties using overlay with 32 P-labelled RIα and RIIα, some of which are shown in Figure 4 (A). As can be seen from the Figure, we were able to construct RIAD analogues that retained their specificity and affinity for RIα although they were heavily replaced with unnatural amino acids. Some selected analogues were synthesized (see Table 1 ) and subjected to a second binding study utilizing the AlphaScreen assay ( Figure 4B ). The results obtained from this assay, in which the peptides, the AKAP and the PKA subunits are maintained in solution, corroborated our previous findings from R overlay studies and proved that the modified peptides were still potent RIα-specific anchoring disruptors. None of the peptides disrupted anchoring of RIIα at the concentrations tested (results not shown).
The stability of the peptides synthesized was assessed by incubation in 30 % (v/v) serum, followed by HPLC and MS analysis of the resulting peaks ( Figure 4C ). The introduction of NmL N-terminally improved the stability of the peptides substantially, resulting in half-lives of more than 150 h in 30 % (v/v) serum for all of the NmL-substituted peptides tested. Notably, this constitutes a 50-fold increase in stability compared with RIAD.
Stabilized RIAD analogues have retained their functionality
The stabilized peptides were tested for PKA binding in vitro by solid-phase pull-down. Analogues synthesized on a cellulose membrane in triplicate were incubated with T-cell lysate overnight, and peptide-bound R subunits were eluted and identified by Western blotting using either anti-RIα or anti-RIIα antibodies for detection ( Figure 4D ). All of the RIAD analogues included bound RIα specifically, although P1 was less efficient at this, which is reflected in the overlay studies described above. Interestingly, P2-P6 appeared to bind RIα to a greater extent than RIAD itself, which might also be appreciated in the results from the overlay studies. This is not consistent, however, with the results from the AlphaScreen assay, which provided fairly similar IC 50 values for both RIAD and the analogues.
In a study performed on human primary T-cells, both RIAD and the stabilized analogues were shown to partly reverse the immunosuppressive effect of the cAMP analogue 8-CPT-cAMP, which led to a reduction in the production of IL-2 ( Figure 5 ). The effect of 8-CPT-cAMP on IL-2 production is concentrationdependent and well documented, and previous studies have shown that the immunosuppressive effect may be restored by inhibiting PKA, either by inhibitors or by anchoring disruptors [35, 37, 47] . The stabilized peptides also appeared more potent in restoring IL-2 production than the native RIAD peptide, possibly as a direct consequence of their prolonged half-life, although the present study was not designed to specifically test the potency of the analogues against RIAD.
DISCUSION
The specificity of PKA signalling is ensured by (i) the presence of several different non-redundant isoforms of both the regulatory and catalytic subunits; (ii) targeting of the holoenzymes to subcellular compartments through specific interactions with AKAPs; (iii) co-localization of both PKA and its substrates through scaffolding by the AKAP, sometimes even including PKAspecific phosphatases that serve to terminate the signal; and (iv) temporal and spatial regulation of distinct cAMP pools, facilitated by compartmentalization of PDEs as well as ACs. The compartmentalized anchoring of selected PKA isoforms constitutes an important level of control for this broad-specificity kinase, which serves to highlight the usefulness of isoform-specific anchoring disruptors as a means of modulating PKA activity.
Although the importance of PKA type I for T-cell activation had been established previously [47] , only more recently have we come to appreciate the significance of anchoring in facilitating PKA activity. Williams [48] initially demonstrated that the inhibitory effects of cAMP on T-cells could be blocked in vitro by the Ht31 peptide, suggesting anchored PKA as an important regulator of T-cell activation. Using RIAD, we have demonstrated the importance of anchoring of PKA type I in the regulation of T-cell activation [17] . Thus targeted disruption of PKA type I anchoring was shown to improve the function of T-cells by lowering their threshold for activation through the TCR. Conversely, a study performed on RIIα −/− mice was unable to detect immune functions critically dependent on the RIIα-containing PKA type II [49] . It should be noted, however, that this could be explained by redundancy between the different PKA isoforms, resulting from compensatory up-regulation of either expression or activity of one PKA isoform following the ablation of another. We still know little about the level of redundancy between the various PKA isoforms in different systems, however, and the isoform-specific anchoring disruptors will be instrumental in determining this contextual interplay. Studies of immune function have been performed in RIIα −/− mice, yet investigations concerning the immune function of RIα −/− mice are precluded by the fact that these mice are embryonically lethal [49] . This fact advocates further the use of pharmacological agents in the specific disruption of RIα in vivo, although conditional and targeted knockouts will certainly also prove useful in this respect.
The prospect of using RI-specific anchoring disruptors in vivo has spurred our development of RIAD analogues with enhanced stability. The analogues reported in the present study have a 50-fold improved serum stability compared with the original RIAD peptide and are expected to have a half-life of more than 12 h in vivo, which is often viewed as the limit for a feasible drug ; n = 4). Scrambled RIAD (Scr; grey) was used as negative control. Statistical analyses were performed using the Mann-Whitney U test. *P < 0.05. regimen in animals. Increased resistance to enzymatic degradation in serum was achieved by the introduction of unnatural amino acids. These were carefully selected to produce peptidomimetics imitating the properties of the original RIAD peptide with respect to RIα selectivity. Substitutions according to the N-end rule have also been suggested to improve the enzymatic stability of peptides [50] , but these were unable to sustain PKA type I binding. The same was observed with the introduction of D-amino acids. Finally, the incorporation of a C-terminal nine-residue polyarginine tail ensures efficient delivery across cell membranes.
Whether or not it will be possible to use RIADs as immunomodulatory treatment in vivo depends on the degree of cross-talk with non-immune functions of PKA type I, and whether or not this results in a high degree of side effects. Regardless, the RIADs constitute an important tool in delineating the physiological implications of PKA signalling. Although RIAD may be a costeffective alternative for studies of short duration in vitro, the stabilized analogues meet a need that has come with the wish to perform in vivo studies. Importantly, the improved stability of the stabilized RIAD analogues reported in the present study is an absolute prerequisite for the success of RI-specific anchoring disruption in vivo. In conclusion, we believe these stabilized RIAD analogues to be essential in improving our understanding of the functional importance of isoform-selective PKA anchoring in the living organism.
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